Latham & Watkins has advised Arcus Biosciences. Gunderson Dettmer has advised the underwriters. Arcus Biosciences, a clinical-stage, global biopharmaceutical company listed on the NYSE under the...
Arcus Biosciences Completes $287.5 Million Common Stock Offering
IDEAYA Biosciences’ $350 Million At-the-Market Offering
Latham & Watkins advised IDEAYA Biosciences, Inc. on the offering, and Davis Polk & Wardwell advised Jefferies LLC, as sales agent. IDEAYA Biosciences, Inc. (NYSE: IDYA)...
Ascendis Pharma’s $150 Million Royalty Funding Agreement with Royalty Pharma
Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction, while Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
4D Molecular Therapeutics’ License Agreement with Astellas Pharma
Latham & Watkins advises 4D Molecular Therapeutics on the deal. Astellas Pharma Inc. (TSE: 4503) and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) have announced a license...
IDEAYA Biosciences’ $250 Million At-the-Market Offering
Latham & Watkins LLP advised IDEAYA Biosciences, Inc., while Davis Polk & Wardwell LLP advised Jefferies LLC in the offering. IDEAYA Biosciences, Inc. announced the SEC-registered at-the-market...
4D Molecular Therapeutics’ $120 Million Common Stock Offering
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
IDEAYA Biosciences’ $175 Million Common Stock Public Offering
Latham & Watkins represents IDEAYA Biosciences in the offering. IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the pricing of an underwritten public offering of common stock and...
Sonoma Biotherapeutics’ Collaboration Agreement with Regeneron Pharmaceuticals
Latham & Watkins advised Sonoma Biotherapeutics on the transaction. Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a collaboration to apply their scientific and...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
CytomX’s Research Collaboration With Moderna
Latham & Watkins LLP advised CytomX in the transaction. CytomX Therapeutics, Inc. (NASDAQ: CTMX), a leader in the field of conditionally activated oncology therapeutics and Moderna,...
Bionano Genomics’ Acquisition of Purigen Biosystems
Latham & Watkins LLP represented Purigen in the transaction. Bionano Genomics, Inc. (NASDAQ: BNGO) has entered into a definitive agreement to acquire Purigen Biosystems, Inc., a...